risk-based contamination control strategies.

Common Failure Points Observed in Inspections

Inspections of tablet manufacturing facilities frequently reveal the following issues:

• Incomplete or inaccurate batch manufacturing records
• Cross-contamination risks due to poor facility or equipment design
• Inadequate cleaning validation of blenders, granulators, and compression machines
• Failure to control dust in granulation and compression areas
• Improper segregation of potent and non-potent APIs
• Lack of in-process controls for tablet weight, hardness, and friability
• Poor deviation handling and superficial investigations
• Equipment maintenance gaps and calibration lapses
• Insufficient training of operators in GMP and documentation practices

These deficiencies are commonly reported in FDA warning letters and EMA inspection reports, particularly for facilities producing for export markets.

Root Causes and Contributing Factors

Root causes behind these recurring GMP issues in tablet manufacturing include:

• Legacy facility design not aligned with modern GMP expectations
• Inadequate investment in dust control and segregation systems
• Weak documentation culture and poor batch record practices
• Lack of robust cleaning validation protocols and scientific justification
• Overemphasis on output and productivity over quality assurance
• Limited operator training on GMP compliance and critical process parameters
• Reactive rather than proactive deviation and CAPA management

Addressing these systemic weaknesses requires a cultural shift and greater management accountability.

How to Prevent and Mitigate GMP Failures

Best practices to prevent GMP failures in tablet manufacturing include:

• Designing facilities with appropriate segregation of materials and personnel flow
• Implementing robust dust collection and cleaning systems
• Validating cleaning procedures for worst-case residues and establishing scientifically justified limits
• Conducting in-process controls such as uniformity of weight, hardness, and dissolution testing
• Maintaining up-to-date batch records with real-time data entry
• Providing hands-on GMP training with emphasis on documentation accuracy
• Using electronic batch records to minimize transcription errors
• Conducting regular internal audits with focus on high-risk areas like granulation and compression

These preventive strategies reduce the risk of inspection findings and enhance product quality.

Corrective and Preventive Actions (CAPA)

When non-conformities occur, an effective CAPA system must be applied. The steps include:

1. Document the issue in deviation logs with supporting evidence
2. Conduct structured root cause analysis using tools like Fishbone diagrams or 5-Why
3. Implement corrective actions such as retraining or revising SOPs
4. Introduce preventive measures like facility upgrades or automation
5. Assign responsibilities and timelines for implementation
6. Verify effectiveness of CAPA through follow-up checks and audits
7. Close CAPA only when sustained compliance is demonstrated

A mature CAPA system ensures inspection findings translate into long-term improvements.

Checklist for Internal Compliance Readiness

• Batch manufacturing records accurate, complete, and contemporaneous
• Cleaning validation protocols risk-based and scientifically justified
• Granulation and compression areas equipped with effective dust control
• Cross-contamination controls in place for potent APIs
• In-process testing documented and reviewed by QA
• Deviation investigations thorough and linked to CAPA
• Equipment qualification and calibration records current
• Operator training logs complete and competency-based
• Electronic batch records validated and Part 11 compliant
• Management review includes trending of GMP issues

This checklist helps OSD facilities maintain continuous compliance readiness for inspections.

Conclusion: Sustaining Compliance Through Proactive Systems

Tablet manufacturing plants often struggle with recurring GMP issues such as documentation errors, cleaning validation failures, and cross-contamination risks. These deficiencies undermine compliance and patient safety. By investing in modern facility design, robust cleaning and dust control systems, comprehensive operator training, and structured CAPA programs, companies can prevent common failures. Sustained compliance requires not only technical solutions but also a quality culture where GMP principles guide daily operations. Proactive systems and continuous monitoring ensure audit readiness and global regulatory confidence.

Abbreviations

• GMP – Good Manufacturing Practice
• OSD – Oral Solid Dosage
• FDA – Food and Drug Administration
• EMA – European Medicines Agency
• WHO – World Health Organization
• PIC/S – Pharmaceutical Inspection Co-operation Scheme
• CAPA – Corrective and Preventive Action
• SOP – Standard Operating Procedure
• API – Active Pharmaceutical Ingredient
• QMS – Quality Management System

References

• FDA 21 CFR Part 211
• EU GMP Guidelines (EudraLex Volume 4)
• WHO GMP Guidelines
• PIC/S Publications